PAC-1 Enters New Human Trials for Brain Cancer

Nov 27, 2017 / In the News

EurekAlert (Nov. 27) – A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.

https://www.eurekalert.org/pub_releases/2017-11/uoia-cds112717.php

Also in:

* News-Gazette (Nov. 28)
http://www.news-gazette.com/news/local/2017-11-28/ui-scientists-breakthrough-cancer-drug-cleared-clinical-trials.html

* European Pharmaceutical Review (Nov. 29)

https://www.europeanpharmaceuticalreview.com/news/69748/pac-1-temozolomide-anaplastic/